1 / 8

Tigecycline Approved by EMEA, 2006

Tigecycline Approved by EMEA, 2006. Glycylcycline (relative minocycline) Intravenous only licenced for complicated skin and skin structure infections ( CSSSI ) and complicated intra-abdominal infection ( IAI ) dosage for complicated SSSI and IAI: 100mg followed by 50mg 12 hourly. EUCAST view.

foy
Download Presentation

Tigecycline Approved by EMEA, 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TigecyclineApproved by EMEA, 2006

  2. Glycylcycline (relative minocycline) • Intravenous only • licenced for complicated skin and skin structure infections (CSSSI) and complicated intra-abdominal infection (IAI) • dosage for complicated SSSI and IAI: 100mg followed by 50mg 12 hourly

  3. EUCAST view • clinically useful activity against staphylococci, β-haemolytic streptococci, enterococci, E. coli, Klebsiella spp, and several other Enterobacteriaceae. • promising but unproven activity against Acinetobacter and several anaerobes which have not received breakpoints. • EUCAST does not consider tigecycline active against Pseudomonas aeruginosa and some species of Enterobacteriacae (Proteus, Morganella and Providencia) which have not received breakpoints.

  4. Tigecycline activity www.eucast.org

  5. Tigecycline pharmacokinetics

More Related